Mpc-6827

Metastatic Melanoma

Myrexis Inc.Phase 1/2Dormant

CC

46/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 37/ 100
Competitive Position: 73/ 100

Competitive context

87 Active assets in the Metastatic Melanoma cohort.

Asset / Sponsor	Phase	Rating
DACARBAZINE Shanghai Junshi Bioscience Co., Ltd.	Phase 4	BBB
Nivolumab Bristol-Myers Squibb	Phase 4	BB
TIL East Metropolitan Health Service, Australia	Phase 2	BB
Ipilimumab NYU Langone Health	Phase 4	BB
Irinotecan Melanoma and Skin Cancer Trials Limited	Phase 2	BB

View all 50 →

Same molecule, other indications

Mpc-6827 is also rated in:

Glioblastoma MultiformeDormant

BB

Indicative ·

64 / 100

Refractory Solid TumorsDormant

CC

Indicative ·

46 / 100

neurodegenerative diseaseDormant

CC

Indicative ·

43 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.